Table 2.
Characteristics of patients divided by age quartiles when they reached ESKD
| Patient characteristic | Age groups (at ESKD), y |
||
|---|---|---|---|
| Q1 (<47 y) n = 74 | Q2+Q3 (47–61 y) n = 141 | Q4 (>61 y) n = 75 | |
| Male, n (%) | 45 (61) | 59 (42) | 34 (45) |
| Mayo Imaging Class,n(%) | |||
| 1E | 49 (66) | 19 (14) | 1 (1) |
| 1D | 22 (30) | 57 (40) | 11 (16) |
| 1C | 3 (4) | 57 (40) | 28 (40) |
| 1B | 0 (0) | 8 (6) | 22 (32) |
| 2B | 0 (0) | 0 (0) | 8 (11) |
| Mutation type or strength, n (%) | n = 53 | n = 89 | n = 40 |
| PKD1T-PKD1NT1 | 55 (95) | 72 (81) | 17 (42) |
| PKD1NT2-PKD2 | 3 (5) | 17 (19) | 23 (58) |
| Macrovascular disease, n (%) | 6 (8) | 25 (18) | 30 (40) |
| Framingham score, | n = 62 | n = 114 | n = 40 |
| % mean ± SD | 7.5 ± 4.2 | 14.5 ± 9.4 | 23.5 ± 11.6 |
ESKD, end-stage kidney disease.